MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.730
+0.140 (8.81%)
At close: Sep 18, 2026, 4:00 PM EDT
1.720
-0.010 (-0.58%)
After-hours: Sep 18, 2026, 7:30 PM EDT
MetaVia Market Cap
MetaVia has a market cap or net worth of $11.4 million as of September 18, 2026. Its market cap has decreased by -55.57% in one year.
Market Cap
11.40M
Enterprise Value
-1.06M
1-Year Change
-55.57%
Ranking
Category
Stock Price
$1.73
ChartMarket Cap Chart
Since December 31, 2019, MetaVia's market cap has decreased from $104.41B to $11.40M, a decrease of -99.99%. That is a compound annual growth rate of -74.27%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 11.40M | -38.51% |
| Dec 31, 2025 | 18.54M | 5.97% |
| Dec 31, 2024 | 17.49M | -2.47% |
| Dec 29, 2023 | 17.93M | 31.75% |
| Dec 30, 2022 | 13.61M | -58.04% |
| Dec 31, 2021 | 32.44M | -62.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| BioLineRx | 11.24M |
| Theriva Biologics | 11.11M |
| KALA BIO | 10.92M |
| Azitra | 10.79M |
| Purple Biotech | 10.65M |
| Immuron | 10.56M |
| IN8bio | 10.55M |
| CytoMed Therapeutics | 10.48M |